NCT04880577View on ClinicalTrials.gov

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 15, 2022

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2025

Conditions

Multiple Sclerosis, Relapsing-RemittingFatigue

Interventions

DRUG

TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]

The study is designed to add on TAF to anti-CD20 therapies

DRUG

Placebo

Placebo arm

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Massachusetts General Hospital

OTHER